Show
Sort by
-
Ultra-deep sequencing and single cell multi-omics characterize measurable residual disease and identify therapy-survived clone in pediatric acute myeloid leukemia
-
Nidogen-1, a novel player in KMT2A-rearranged pediatric acute myeloid leukemia patients, expressed in the leukemic stem cell
-
- Journal Article
- A1
- open access
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update
-
Domain specificity of anti-prothrombin antibodies that express lupus anticoagulant activity
-
A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-Cell malignancies
-
The phase 2 CARTITUDE-2 trial : updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)
-
Englumafusp alfa (CD19-4-1BBL) and glofitamab combination in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) : biomarker results from a phase I dose-escalation trial
-
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in Belgium after 4 years
-
Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel : phase 2 Elara 3-year follow-up
-
Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers